THE latest issue of the NPS
Radar has been released online,
containing independent, evidencebased
assessments of new drugs
and new PBS listings.
This month’s issue covers two of
the new class of dipeptidyl
peptidase-4 (DPP-4) inhibitors
sitagliptin (Januvia) and vildagliptin
(Galvus), as well as the new
autoinjector Anapen and reviews
and info on Panadol Extra,
Colchicine for acute gout,
pramipexole (Sifrol ER), Anakinra
(Kineret) and Exenatide (Byetta).
See www.nps.org.au/radar.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Aug 10
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.